A Split-Marker System for CRISPR-Cas9 Genome Editing in Methylotrophic Yeasts

Abstract

Methylotrophic yeasts such as Ogataea polymorpha and Komagataella phaffii (sin. Hansenula polymorpha and Pichia pastoris, respectively) are commonly used in basic research and biotechnological applications, frequently those requiring genome modifications. However, the CRISPR-Cas9 genome editing approaches reported for these species so far are relatively complex and laborious. In this work we present an improved plasmid vector set for CRISPR-Cas9 genome editing in methylotrophic yeasts. This includes a plasmid encoding Cas9 with a nuclear localization signal and plasmids with a scaffold for the single guide RNA (sgRNA). Construction of a sgRNA gene for a particular target sequence requires only the insertion of a 24 bp oligonucleotide duplex into the scaffold. Prior to yeast transformation, each plasmid is cleaved at two sites, one of which is located within the selectable marker, so that the functional marker can be restored only via recombination of the Cas9-containing fragment with the sgRNA gene-containing fragment. This recombination leads to the formation of an autonomously replicating plasmid, which can be lost from yeast clones after acquisition of the required genome modification. The vector set allows the use of G418-resistance and LEU2 auxotrophic selectable markers. The functionality of this setup has been demonstrated in O. polymorpha, O. parapolymorpha, O. haglerorum and Komagataella phaffii.

CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review

“…The outcomes are diverse, often causing frameshift mutations and depleting the target gene function [42,43]. While lacking precision, NHEJ operates without a donor template, functions in both dividing and nondividing cells, and is generally more efficient [44,45]. Guided RNA (gRNA) (A) and Cas9 (B) form a complex (C), followed by targeting (D) of the specific gene.…”

CRISPR-Cas Technology for Bioengineering Conventional and Non-Conventional Yeasts: Progress and New Challenges

“…Methylotrophic yeasts like Komagataella phaffii (formerly known as Pichia pastoris) and Ogataea polymorpha find extensive use in both fundamental research and biotechnological applications, often in contexts necessitating genetic alterations [81,82]. Pichia pastoris is often used to produce heterologous proteins, in which CRISPR-Cas9 system using RNA pol II promoter was first established in 2016 [83].…”

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

“…Given that there are no ethical considerations, the experimental time is relatively short, and the expense is minimal, cell models are commonly used to explore many neurological illnesses, including ALS. Furthermore, recent advances in CRISPR/Cas9 technology allow researchers to precisely target and introduce modifications in the genomic DNA of different cell lines (Kramer et al, 2018;Karginov et al, 2023). The introduction of the CRISPR/Cas9 system has facilitated the development of numerous ALS cell models, such as HT22, iPSCs, BV2, Neuro 2a, NSC-34, hESC, and HeLa cell lines, etc.…”